AbbVie After Purchase Apogee? Is It a Buy Now for Investors
AbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
What Are Target Date Funds Retirement introduces target date funds, explaining how age-based allocations can simplify retirement investing.
19,788 articlesAbbVie is expanding its immunology portfolio with Apogee Therapeutics. This guide explains what the deal adds, how it...
A Brazil fintech quietly links USDT to the Pix payments rail, creating a behind-the-scenes bridge that could redefine...
Tech stocks just their footing as an AI spending surge loses steam. The sector faced a rough week, driven by slower d...
Investor participation in crypto funding fell to 651 in Q2 2026, the lowest since 2020, underscoring a tighter, more ...
Strategy pauses bitcoin buys as the firm unveils a $1 billion digital credit repurchase program, boosting cash reserv...
Artificial intelligence is turbocharging drug discovery, cutting years from development timelines and sparking a surg...
Forward Industries jumped after confirming it expanded its SOL holdings by more than 500,000 coins. Here’s what this ...
McDonald’s raised its quarterly dividend again as franchisees contend with higher costs and softer consumer demand. T...
As 2026 unfolds, investors debate whether ripple worth holding through the year hinges on regulatory clarity, adoptio...
JEPI investors missed 13.21% gains in a strong market as an options overlay muted upside and taxes eroded income. Thi...
MicroStrategy is monetizing BTC to back dividends and bolster liquidity, draining a portion of its planned sale capac...
Tech-focused investors watched TeraWulf surge after a major AI data-center lease deal, signaling potential recurring ...